Published on 24/12/2025
Clinical Supply Chain Challenges in the United Kingdom
The success of a clinical trial relies not only on strong protocols and regulatory compliance but also on a robust clinical supply chain. In the United Kingdom (UK), clinical trial logistics face unique challenges shaped by regulatory requirements from the Medicines and Healthcare products Regulatory Agency (MHRA), operational constraints within the National Health Service (NHS), and systemic changes following Brexit. Ensuring timely delivery, accountability, and integrity of investigational medicinal products (IMPs) is critical for trial quality and participant safety.
This article explores the key challenges of clinical supply chains in the UK, including import and export licensing, packaging and labelling requirements, NHS capacity limitations, cold chain maintenance, and the growing impact of decentralized and globalised trial models.
Background and Regulatory Framework
MHRA Oversight of Clinical Supplies
MHRA requires that all IMP manufacturing, storage, and distribution comply with Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP). Sponsors must ensure Qualified Person (QP) release of all IMP batches prior to supply to NHS sites.
Import and Export Requirements
Post-Brexit, IMP import into the UK requires a clinical trial import licence, while exports to EU countries must comply with EU GDP rules. This
Packaging and Labelling Standards
IMP packaging must comply with UK-specific labelling guidance, ensuring that information such as expiry dates, storage conditions, and trial codes are clear and compliant with GCP and MHRA expectations.
Core Supply Chain Challenges in the UK
1. Brexit-Related Delays
Border controls and new customs procedures have caused delays in transporting IMPs between the UK and EU. Sponsors must account for extended lead times and develop contingency plans.
2. NHS Storage and Distribution Limitations
Many NHS Trusts lack advanced warehousing capacity for IMPs, particularly for cold chain products. Sponsors often need to contract with third-party logistics providers.
3. Cold Chain Management
Temperature-sensitive biologics and vaccines require continuous monitoring. MHRA inspections frequently identify deficiencies in temperature mapping and excursion management.
4. Accountability and Documentation
IMP receipt, storage, dispensing, and destruction records must be contemporaneous and TMF-ready. Audit trails are a frequent area of MHRA inspection findings.
5. Decentralised and Home Delivery Models
The rise of decentralized trials has introduced new complexities for home delivery of IMPs, requiring validated courier systems and clear patient handling instructions.
Best Practices for Managing UK Clinical Supply Chains
- Engage QPs early to ensure smooth batch release and import clearance.
- Use validated third-party logistics partners for NHS sites lacking capacity.
- Implement continuous temperature monitoring and excursion response plans.
- Maintain digital accountability systems for IMP records to support MHRA inspections.
- Plan Brexit-related contingencies, including duplicate storage in UK and EU.
Scientific and Regulatory Evidence
- Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended)
- MHRA Guidance on GMP and GDP for Clinical Trials
- ICH Q7 – Good Manufacturing Practice
- EU GDP Guidelines (for EU-UK exports)
- MHRA GCP Inspection Metrics on Supply Chain Findings
Special Considerations
- Oncology Trials: Require robust cold chain management due to biological therapies and combination regimens.
- Rare Disease Trials: Small-scale supplies need just-in-time manufacturing and efficient distribution networks.
- Pediatrics: Child-specific formulations require special labelling and packaging considerations.
- Advanced Therapies (ATMPs): Gene and cell therapies often need cryogenic storage and highly specialised logistics.
When Sponsors Should Seek Regulatory Advice
- If importing IMPs from the EU under new licensing requirements.
- When designing home delivery systems for decentralized trials.
- If using third-party logistics providers with limited MHRA inspection history.
- For ATMPs requiring cryogenic supply chain solutions.
- When Brexit-related supply chain delays may affect trial timelines.
FAQs
1. What are the main regulatory requirements for IMP supply in the UK?
IMP supply must comply with MHRA’s GMP/GDP guidance, QP release, and licensing requirements for import and distribution.
2. How has Brexit affected UK trial supply chains?
Brexit introduced customs procedures and dual compliance obligations, increasing lead times and documentation needs.
3. Do NHS sites have adequate storage for IMPs?
Many NHS sites face capacity limitations, particularly for cold chain storage, requiring third-party logistics support.
4. Can IMPs be delivered directly to patients at home?
Yes, provided validated courier systems and documentation are in place to maintain GCP and MHRA compliance.
5. What are common MHRA inspection findings in supply chains?
Temperature excursion management failures, delayed documentation, and inadequate CRO oversight are frequent issues.
6. Who is responsible for IMP accountability?
Sponsors retain ultimate responsibility, but CROs and NHS sites must maintain accurate records and support inspections.
7. How do supply chains differ for ATMPs?
ATMPs often require cryogenic logistics and long-term follow-up, adding complexity to trial supply chains.
Conclusion
Clinical supply chain management in the UK is a complex but vital aspect of trial success. With MHRA enforcing strict standards, Brexit reshaping import/export dynamics, and NHS sites facing infrastructure challenges, sponsors must adopt proactive strategies. Validated logistics partners, QP engagement, and robust documentation systems are essential to ensure timely, compliant, and safe delivery of IMPs. As trials evolve toward decentralised and advanced therapies, supply chain resilience will remain a critical factor in UK clinical research.